{
  "items": [
    {
      "id": "jbX-QS7P",
      "url": "https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Jul 2, 2025 10:19am",
      "snippet": "In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "E9KnfVkc",
      "url": "https://www.fiercepharma.com/pharma/amgens-chemocentryx-prevails-investor-lawsuit-around-autoimmune-drug-tavneos",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 19, 2025 9:58am",
      "snippet": "Dogged for several years by an investor lawsuit accusing the company of misleading investors about the safety and efficacy of its now-approved drug Tavneos, ChemoCentryx has emerged victorious in a securities fraud complaint.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "NuL2YO87",
      "url": "https://www.fiercepharma.com/biotech/csl-lay-15-workforce-cut-rd-costs-and-spin-out-vaccine-unit",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 19, 2025 4:33am",
      "snippet": "CSL is laying off up to 15% of its workforce as the company looks to cut R&amp;D costs and spin out its vaccine subsidiary.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "cmAQkVRF",
      "url": "https://www.fiercepharma.com/pharma/sarepta-shares-more-elevidys-safety-data-response-patient-group-fda-petition",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 10:56am",
      "snippet": "Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy patient group petitions the FDA to update the medicine’s label.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "39MdEmWV",
      "url": "https://www.fiercepharma.com/pharma/vanda-scores-landmark-win-over-fda-years-long-dispute-over-hetlioz-jet-lag-disorder-bid",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 11:05am",
      "snippet": "An appeals court overturned a prior FDA action in a years-long face-off between Vanda and the agency over a delayed hearing for Vanda's jet lag disorder hopeful Hetlioz.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "obQiuMuC",
      "url": "https://www.fiercepharma.com/marketing/novo-nordisk-unveils-499-cash-pay-ozempic-offering-amid-continued-compounder-competition",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 11:02am",
      "snippet": "Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for a monthly supply of Wegovy, Novo Nordisk is expanding the discount to its other GLP-1 heavyweight.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "wEapQErW",
      "url": "https://www.fiercepharma.com/pharma/conflicts-interests-cdcs-vaccine-panel-historic-low-when-rfk-jrs-hhs-purged-committee-remove",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 2:02pm",
      "snippet": "Earlier this summer, HHS Secretary Robert F. Kennedy ousted all members of the CDC's vaccine advisory committee in an effort to remove industry influence. But according to a new study, industry-related conflicts of influence had already been \"virtually eliminated\" for years.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ggwcuujR",
      "url": "https://www.fiercepharma.com/pharma/novos-wegovy-picks-3rd-indication-fda-approval-severe-liver-disease-mash",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 9:43am",
      "snippet": "The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis. The green light tees up a likely showdown with Madrigal Pharmaceuticals' approved drug Rezdiffra in the severe form of fatty liver diseas",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "r8f2E2W9",
      "url": "https://www.fiercepharma.com/sponsored/ai-media-and-evolution-omnichannel-healthcare-marketing-ray-rosti-episode-3-next",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 6, 2025 3:50pm",
      "snippet": "Klick Media’s President shares his perspective on how AI is redefining planning, analytics and micro-segmentation in HCP marketing",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "sq_FYhOq",
      "url": "https://www.fiercepharma.com/sponsored/fedegaris-fob5-redefines-sterilization-compact-design-and-full-gmp-compliance",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 13, 2025 9:58am",
      "snippet": "Discover how Fedegari’s FOB5 is redefining sterilization with compact design, GMP compliance &amp; high-containment capabilities.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6500000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 2,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "ElEgmIuj",
      "url": "https://www.fiercepharma.com/pharma/fiercest-women-life-sciences-2025-nominations-open-now",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 12:13pm",
      "snippet": "Every year, Fierce celebrates women making a powerful impact across biopharma and medtech. It’s time once again to make your suggestions for this year’s honorees.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Q47GYJPj",
      "url": "https://www.fiercepharma.com/pharma/tonixs-tonmya-gains-fda-nod-becoming-first-new-fibromyalgia-treatment-more-16-years",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 4:57pm",
      "snippet": "Tonix Pharmaceuticals was founded in 2010 to develop and bring to market a drug for fibromyalgia. Fifteen years later, the New Jersey company has accomplished its mission with an FDA sign-off for Tonmya.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "hf_-AEV3",
      "url": "https://www.fiercepharma.com/pharma/lundbeck-dials-migraine-drug-us-peak-sales-stays-positive-rexulti-ptsd-use",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 10:09am",
      "snippet": "After a 54% year-over-year sales increase for CGRP migraine drug Vyepti in the U.S., Lundbeck has raised its peak sales projection for the therapy in the key market.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Q5dhOn4c",
      "url": "https://www.fiercepharma.com/pharma/amgen-skirts-50m-payout-blincyto-patent-litigation-tiff-lindis",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 9:55am",
      "snippet": "U.S. District Judge Gregory Williams concluded that two patents held by Lindis Biotech “are unenforceable due to inequitable conduct.” The decision negates the $50.3 million jury verdict Lindis won in December over allegations that Amgen’s Blincyto violated Lindis-held intellectu",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "5NU13kkc",
      "url": "https://www.fiercepharma.com/marketing/astrazeneca-begins-dtc-home-delivery-self-administered-flumist-vaccine",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 10:06am",
      "snippet": "Nearly a year after earning the first-ever FDA approval for a self-administered flu vaccine, AstraZeneca has kicked off a new service delivering its FluMist directly to consumers.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "3bf7N8mT",
      "url": "https://www.fiercepharma.com/pharma/battle-obesity-drug-heavyweights",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 3:22pm",
      "snippet": "In this episode of \"The Top Line,\" we unpack how Novo Nordisk and Eli Lilly’s latest earnings, pipeline moves and rising competition are reshaping the high-stakes race in obesity drugs.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "wLSsQrK1",
      "url": "https://www.fiercepharma.com/pharma/precigen-scores-fda-nod-first-ever-treatment-hpv-related-disorder",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 8:21am",
      "snippet": "The FDA has approved a treatment for recurrent respiratory papillomatosis for the first time. The agency has signed off on Precigen’s Papzimeos, a non-replicating adenoviral vector-based immunotherapy, which can eliminate the need for repeated surgical interventions to remove ben",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "dUPAgd5K",
      "url": "https://www.fiercepharma.com/pharma/padcev-new-breakthrough-alzheimers-drug-grim-fate-fosun-645m-deal",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 6:00pm",
      "snippet": "The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. Fosun Pharma is out-licensing its DPP1 inhibitor for up to $645 million. And more.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "OwVw8ghh",
      "url": "https://www.fiercepharma.com/pharma/hhs-revives-90s-task-force-designed-improve-safety-childhood-vaccines",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 3:29pm",
      "snippet": "The Department of Health and Human Services is relaunching a task force focused on the safety of childhood vaccines. The federal panel will be chaired by National Institutes of Health Director Jay Bhattacharya, M.D., Ph.D.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "GXM1SFZj",
      "url": "https://www.fiercepharma.com/pharma/eli-lilly-endorses-trumps-goal-aligning-international-drug-prices",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 1:22pm",
      "snippet": "Eli Lilly said it has \"intensified efforts to&nbsp;align prices across developed countries\" in recent months. Besides a new U.K. price hike, Lilly said it may make other \"necessary pricing adjustments\" by Sept. 1.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "HzWX-jRW",
      "url": "https://www.fiercepharma.com/marketing/enhertu-keytruda-promos-put-az-merck-front-oncology-hcp-marketing-pack-report",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 11:53am",
      "snippet": "An analysis of how cancer drugmakers interact with oncologists found, perhaps unsurprisingly, that those interactions are dominated by therapies boasting a broad reach and targeting the most common cancers.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "yZdh_svo",
      "url": "https://www.fiercebiotech.com/medtech/medtronic-expands-board-chase-ma-efficiencies-activist-investor-takes-stake",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 10:27am",
      "snippet": "The company’s newest stakeholder, Elliott Investment Management, said it has become one of Medtronic's largest investors.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "yKjMYHsv",
      "url": "https://www.fiercebiotech.com/biotech/ptc-therapeutics-friedreichs-ataxia-hopes-derailed-crl-fda",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 10:32am",
      "snippet": "Despite missing its primary endpoint in a phase 3 study, PTC had held out hope that another endpoint would help its candidate pass muster with the FDA.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "QLaQ7spq",
      "url": "https://www.fiercebiotech.com/biotech/fda-pushes-back-pdufa-date-regenxbios-hunter-syndrome-gene-therapy",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 9:08am",
      "snippet": "Delays from the Food and Drug Administration continue to pile up, with Maryland-based Regenxbio the latest to report the review of one of its assets has been extended.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "WFWD2bcx",
      "url": "https://www.fiercebiotech.com/biotech/viking-hits-stormy-seas-phase-2-oral-obesity-data-sink-stock",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 9:21am",
      "snippet": "Viking Therapeutics has reported phase 2 data on its oral obesity drug candidate, linking the peptide to weight loss of up to 12.2% after 13 weeks. But with 38% of patients discontinuing treatment at the most effective dose, investors sent the stock down 37% in premarket trading.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "tieBM7t5",
      "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Dec 23, 2024 11:52am",
      "snippet": "As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "I7ZDh7pR",
      "url": "https://www.fiercebiotech.com/biotech/opthea-still-reeling-eye-disease-flops-ramps-layoffs-85-and-loses-ceo",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 5:32am",
      "snippet": "Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures, but the company isn’t quite ready to give up.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.39999999999999997,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "HwpUXT7x",
      "url": "https://www.fiercebiotech.com/biotech/chinas-remegen-sells-asia-rights-vegffgf-eye-drug-180m-deal",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 6:17am",
      "snippet": "China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 million Chinese yuan ($34.8 million) upfront.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "kiGyxqgi",
      "url": "https://www.fiercebiotech.com/biotech/csl-lay-15-workforce-cut-rd-costs-and-spin-out-vaccine-unit",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 4:33am",
      "snippet": "CSL is laying off up to 15% of its workforce as the company looks to cut R&amp;D costs and spin out its vaccine subsidiary.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "zptqQjZQ",
      "url": "https://www.fiercebiotech.com/biotech/shankar-ramaswamys-gene-therapy-biotech-raises-313m",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 4:29pm",
      "snippet": "Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Ge0gx7LW",
      "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Dec 23, 2024 12:22pm",
      "snippet": "The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "5sM6xtXU",
      "url": "https://www.fiercebiotech.com/biotech/genentechs-summer-struggle-continues-scrapped-2b-cell-therapy-deal",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 2:14pm",
      "snippet": "Genentech’s summer of downsizing and cost-cutting continued this morning, with the Roche subsidiary announcing the termination of a cell therapy deal worth as much as $2 billion. The pact with Adaptive Biotechnologies, originally launched in January 2019, was meant to see Genente",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "SbKGbpgW",
      "url": "https://www.fiercebiotech.com/cro/private-equity-firm-acquires-clinical-trial-site-network-headlands-research",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 12:05pm",
      "snippet": "After years of striking acquisitions to build up its site network, Headlands Research has now been bought itself. Headlands has been scooped up by private equity firm THL Partners, which entered an agreement to buy the clinical trial company from founding firm KKR.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "CTGGV_09",
      "url": "https://www.fiercebiotech.com/biotech/stealth-bio-submits-fda-application-rare-disease-candidate-third-time-0",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 11:17am",
      "snippet": "After an FDA rejection in May, Stealth BioTherapeutics has resubmitted a new drug application for its investigational treatment designed to treat an ultra-rare genetic disease.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "0pbvvwzF",
      "url": "https://www.fiercebiotech.com/biotech/neurizon-becomes-second-biotech-hit-fda-delay-als-candidate",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 10:48am",
      "snippet": "Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. Neurizon, an Australian biotech focusing on neurodegenerative diseases, will now have to wait until Oct. 3 before receiving a response on whether its amyotr",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "pSDNg4Gh",
      "url": "https://www.fiercebiotech.com/medtech/baxters-novum-iq-corrections-grow-scope-include-syringe-pumps",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 11:05am",
      "snippet": "Last month, Baxter and the FDA highlighted a problem with the Novum IQ large-volume pump, tied to 79 serious injuries and two deaths. Now, separate software issues are affecting both the large-volume system as well as its syringe-based pump.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "YPpsaygg",
      "url": "https://www.fiercebiotech.com/biotech/merck-kgaa-swoops-2b-neurological-disease-pact-skyhawk",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 9:35am",
      "snippet": "Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "03qKxhSU",
      "url": "https://www.fiercebiotech.com/biotech/reunions-psychedelic-prodrug-reduces-post-partum-depression-phase-2-study",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 5:59am",
      "snippet": "Reunion Neuroscience’s psychedelic has reduced the symptoms of postpregnancy depression in a phase 2 study, setting up the biotech to enter late-stage trials next year.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "w7aObQFo",
      "url": "https://www.fiercebiotech.com/biotech/pfizers-scd-drug-fails-phase-3-study-latest-blow-global-blood-therapeutics-legacy",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 4:48am",
      "snippet": "Pfizer’s sickle cell disease drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "oIpshM6R",
      "url": "https://www.fiercebiotech.com/pharma/fiercest-women-life-sciences-2025-nominations-open-now",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 15, 2025 12:13pm",
      "snippet": "Every year, Fierce celebrates women making a powerful impact across biopharma and medtech. It’s time once again to make your suggestions for this year’s honorees.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    }
  ],
  "last_run_at": "2025-08-19T15:56:24.405Z"
}